The Relative Strength (RS) Rating for LENZ Therapeutics climbed into a new percentile Wednesday, with a rise from 69 to 82.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the top-performing stocks typically have an 80 or higher RS Rating in the early stages of their moves.
LENZ Therapeutics has risen more than 5% past a 25.77 entry in a second-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 0% EPS growth last quarter. Revenue gains came in at 0%.
The company earns the No. 189 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
